The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.
hepatocellular carcinoma
inflammatory biomarkers
neutrophil-lymphocyte ratio
platelet-lymphocyte ratio
prognostic nutritional index
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
14
10
2021
revised:
23
11
2021
accepted:
13
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months,
Identifiants
pubmed: 35008350
pii: cancers14010186
doi: 10.3390/cancers14010186
pmc: PMC8750517
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Surg. 2020 Oct 31;20(1):261
pubmed: 33129309
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Oncotarget. 2019 Jun 18;10(40):4018-4025
pubmed: 31258846
JAMA Oncol. 2021 Jan 1;7(1):113-123
pubmed: 33090190
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):234-56
pubmed: 27298100
Br J Cancer. 2019 May;120(11):1033-1036
pubmed: 31061454
JAMA Oncol. 2020 Nov 1;6(11):e204564
pubmed: 33001135
PLoS One. 2020 May 7;15(5):e0232449
pubmed: 32379785
Clin Cancer Res. 2020 Aug 1;26(15):3936-3946
pubmed: 32357963
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Oncol. 2000 Mar;16(3):543-7
pubmed: 10675487
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Curr Treat Options Oncol. 2021 Aug 23;22(10):87
pubmed: 34424422
Br J Cancer. 2012 Apr 10;106(8):1439-45
pubmed: 22433965
Hepatology. 2019 Oct;70(4):1214-1230
pubmed: 30933361
Clin Cancer Res. 2021 Nov 1;27(21):5961-5978
pubmed: 34407972
Liver Int. 2019 Nov;39(11):2008-2023
pubmed: 31433891
J Hepatol. 2020 Dec;73(6):1460-1469
pubmed: 32710922
J Hepatol. 2012 Nov;57(5):1013-20
pubmed: 22732513
Cancer Med. 2020 Jul;9(14):4962-4970
pubmed: 32419290
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Clin Oncol. 2021 Sep 20;39(27):2991-3001
pubmed: 34292792
Hepatology. 2018 Oct;68(4):1347-1360
pubmed: 29631332
Oncotarget. 2017 Feb 28;8(9):14408-14415
pubmed: 28122337